Sheaff Brock Investment Advisors LLC lowered its stake in shares of Stryker Corporation (NYSE:SYK) by 19.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,350 shares of the medical technology company’s stock after selling 800 shares during the quarter. Sheaff Brock Investment Advisors LLC’s holdings in Stryker were worth $476,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds also recently added to or reduced their stakes in the business. BB&T Investment Services Inc. raised its holdings in Stryker by 150.9% during the third quarter. BB&T Investment Services Inc. now owns 3,159 shares of the medical technology company’s stock worth $455,000 after purchasing an additional 1,900 shares in the last quarter. Stifel Financial Corp grew its position in shares of Stryker by 13.3% during the third quarter. Stifel Financial Corp now owns 148,706 shares of the medical technology company’s stock worth $21,132,000 after acquiring an additional 17,453 shares during the last quarter. San Francisco Sentry Investment Group CA grew its position in shares of Stryker by 47.8% during the third quarter. San Francisco Sentry Investment Group CA now owns 1,005 shares of the medical technology company’s stock worth $143,000 after acquiring an additional 325 shares during the last quarter. Brookmont Capital Management grew its position in shares of Stryker by 9.5% during the third quarter. Brookmont Capital Management now owns 5,979 shares of the medical technology company’s stock worth $849,000 after acquiring an additional 518 shares during the last quarter. Finally, Commerzbank Aktiengesellschaft FI grew its position in shares of Stryker by 352.4% during the third quarter. Commerzbank Aktiengesellschaft FI now owns 49,160 shares of the medical technology company’s stock worth $6,982,000 after acquiring an additional 38,293 shares during the last quarter. 74.97% of the stock is currently owned by institutional investors.
A number of equities analysts have recently issued reports on SYK shares. Robert W. Baird upgraded shares of Stryker from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $161.00 to $173.00 in a research report on Thursday, November 16th. SunTrust Banks restated a “buy” rating and set a $161.00 target price on shares of Stryker in a research report on Friday, November 17th. Wells Fargo & Company raised their target price on shares of Stryker from $160.00 to $166.00 in a research report on Friday, October 27th. Barclays raised their target price on shares of Stryker from $137.00 to $148.00 and gave the stock an “underweight” rating in a research report on Friday, October 27th. Finally, Oppenheimer restated a “hold” rating on shares of Stryker in a research report on Wednesday, August 23rd. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $152.10.
Stryker Corporation (SYK) traded down $0.33 during trading hours on Wednesday, reaching $152.03. 982,400 shares of the company were exchanged, compared to its average volume of 1,181,520. Stryker Corporation has a 1 year low of $111.22 and a 1 year high of $160.62. The company has a current ratio of 2.37, a quick ratio of 1.61 and a debt-to-equity ratio of 0.63. The stock has a market cap of $57,018.84, a price-to-earnings ratio of 24.15, a price-to-earnings-growth ratio of 2.40 and a beta of 0.78.
Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, October 26th. The medical technology company reported $1.52 earnings per share for the quarter, beating analysts’ consensus estimates of $1.50 by $0.02. Stryker had a net margin of 14.67% and a return on equity of 24.11%. The firm had revenue of $3.01 billion for the quarter, compared to analyst estimates of $2.97 billion. During the same period last year, the firm posted $1.39 EPS. Stryker’s quarterly revenue was up 6.1% on a year-over-year basis. equities research analysts anticipate that Stryker Corporation will post 6.47 earnings per share for the current year.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.